Clinical trials in amyotrophic lateral sclerosis: The tenuous past and the promising future

Journal of Clinical Pharmacology

Volumn 45, Issue 12, 2005, Pages 1334-1344

  Choudry, Rabia B ^a   Cudkowicz, Merit E ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Amyotrophic lateral sclerosis; Clinical trials; Drug trials

Indexed keywords

ACETYLCYSTEINE; AEOL 10150; ALPHA TOCOPHEROL; AMOXICILLIN; AMPA RECEPTOR ANTAGONIST; ANTIOXIDANT; APOPTOSIS INHIBITOR; BETA LACTAM ANTIBIOTIC; BETA1A INTERFERON; BRAIN DERIVED NEUROTROPHIC FACTOR; BUTYRIC ACID DERIVATIVE; CEFTRIAXONE; CELECOXIB; CREATINE; CYCLOOXYGENASE 2 INHIBITOR; CYCLOPHOSPHAMIDE; DEXTROMETHORPHAN; GABAPENTIN; LAMOTRIGINE; MINOCYCLINE; NEUROTROPHIC FACTOR; OMIGAPIL; PENICILLIN G; RECOMBINANT CILIARY NEUROTROPHIC FACTOR; RECOMBINANT SOMATOMEDIN C; RILUZOLE; ROFECOXIB; TALAMPANEL; TCH 346; TOPIRAMATE; UBIDECARENONE; UNINDEXED DRUG; VERAPAMIL;

AMYOTROPHIC LATERAL SCLEROSIS; CLINICAL TRIAL; DISEASE COURSE; DRUG ACTIVITY; DRUG SCREENING; HUMAN; NONHUMAN; REVIEW; SIDE EFFECT;

AMYOTROPHIC LATERAL SCLEROSIS; ANIMALS; ANTIOXIDANTS; APOPTOSIS; CLINICAL TRIALS; EXCITATORY AMINO ACID ANTAGONISTS; FORECASTING; HUMANS; NERVE GROWTH FACTORS;

EID: 27844432628     PISSN: 00912700     EISSN: None     Source Type: Journal    
DOI: 10.1177/0091270005282631     Document Type: Review

References (79)

1. Cleveland D, Rothstein J. From Charcot to Lou Gehrig: deciphering selective motor neuron death in ALS. Nat Rev Neurosci. 2001;2:806-819.
2. Rowland L, Shneider N. Amyptrophic lateral sclerosis. N Engl J Med. 2001;344:1688-1700.
3. Noonan CW, White MC, Thurman D, Wong LY. Temporal and geographic variation in United States motor neuron disease mortality, 1969-1998. Neurology. 2005;64:1215-1221.
4. Drachman D, Chaudry V, Cornblath D, et al. Trial of immunosuppression in amyotrophic lateral sclerosis using total lymphoid irradiation. Ann Neurol 1994;35:142-150.
5. Beghi E, Chio A, Inghilleri M, et al. A randomized controlled trial of recombinant interferon beta-1a in ALS. Italian Amyotrophic Lateral Sclerosis Study Group. Neurology. 2000;54:469-474.
6. Smith SA, Miller, RG, Murphy JR, Rigel SP. Treatment of ALS with high dose pulse cyclophosphamide. J Neurol Sci. 1994;124(Suppl):84-87.
7. Rothstein J, Kuncl RW. Neuroprotective strategies in a model of chronic glutamate-mediated motor neuron toxicity. J Neurochem. 1995;65:643-651.
8. Pasinelli P, Borchelt DR, Houseweart MK, Cleveland DW, Brown RH. Caspase-1 is activated in neural cells and tissue with amyotrophic lateral sclerosis-associated mutations in copper-zinc superoxide dismutase. Proc Natl Acad Sci USA. 1998;95:15763-15768.
9. Pasinelli P, Houseweart MK, Brown RH, Cleveland, DW. Caspase-1 and -3 are sequentially activated in motor neuron death in Cu/Zn superoxide dismutase mediated familial amyotrophic lateral sclerosis. Proc Natl Acad Sci USA. 2000;97:13901-13906.
10. Flanagan S, Anderson RD, Ross MA, Oberley LW. Overexpression of manganese superoxide dismutase attenuates neuronal death inhuman cells expressing mutant (G37R) Cu/Zn-superoxide dismutase. J Neurochem. 2002;81:170-177.
11. Gurney ME, Pu H, Chiu AY, et al. Motor neuron degeneration in mice that express a human Cu/Zn superoxide dismutase mutation. Science. 1994;264:1772-1775.
12. Ghadge G, Lee JP, Bindokas VP, et al. Mutant superoxide dismutase-1-linked familial amyotrophic lateral sclerosis: molecular mechanisms of neuronal death and protection. J Neurosci. 1997;17: 8756-8766.
13. Doble A, Kennel P. Animal models of amyotrophic lateral sclerosis. Amyotroph Lateral Scler Other Motor Neuron Disord. 2000;1:301-312.
14. Wong P, Pardo CA, Borchelt DR, et al. An adverse property of a familial ALS-linked SOD1 mutation causes motor neuron disease characterized by vacuolar degeneration of mitochondria. Neuron. 1995; 14:1105-1116.
15. Pioro EP, Mitsumoto H. Animal models of ALS. Clin Neurosci. 1995;3:375-385.
16. Heemskerk J. High throughput drug screening. Amyotroph Lateral Scler Other Motor Neuron Disord. 2004;5(Suppl 1):19-21.
17. Rothstein JD, Dykes-Hoberg M, Pardo CA, et al. Knockout of glutamate transporters reveals a major role for astroglial transport in excitotoxicity and clearance of glutamate. Neuron. 1996;16:675-686.
18. Danbolt N. Glutamate uptake. Prog Neurobiol. 2001;65:1-105.
19. Rothstein JD, Patel S, Regan MR, et al. Beta-lactam antibiotics offer neuroprotection by increasing glutamate transporter expression. Nature. 2005;433:73-77.
20. Riviere M, Meininger V, Zeisser P, Munsat T. An analysis of extended survival in patients with amyotrophic lateral sclerosis treated with riluzole. Arch Neurol. 1998;55:526-528.
21. Estevez AG, Stutzmann JM, Barbeito L. Protective effect of riluzole on excitatory amino acid-mediated neurotoxicity in motoneuron-enriched cultures. Eur J Pharmacol. 1995;280:47-53.
22. Gurney ME, Fleck TJ, Himes CS, Hall ED. Riluzole preserves motor function in a transgenic model of familial amyotrophic lateral sclerosis. Neurology. 1998;50:62-66.
23. Kennel P, Revah F, Bohme GA, et al. Riluzole prolongs survival and delays muscle strength deterioration in mice with progressive motor neuronopathy (pmn). J Neurol Sci. 2000;180:55-61.
24. Taylor C. Gabapentin: mechanisms of action. In: Levy R, Mattson R, Medlrum B, eds. Antiepileptic Drugs. 4th ed. New York: Raven; 1995:829-841.
25. Gurney ME, Cutting FB, Zhai P, et al. Benefit of vitamin E, riluzole, and gabapentin in a transgenic model of familial amyotrophic lateral sclerosis. Ann Neurol. 1996;39:147-157.
26. Miller RG, Moore DH, Young LA, WALS Study Group. Placebo-controlled trial of gabapentin in patients with amyotrophic lateral sclerosis. Neurology. 1996;47:1383-1388.
27. Miller RG, Moore DH, Gelinas DF, et al. Phase III randomized trial of gabapentin in patients with amyotrophic lateral sclerosis. Neurology. 2001;56:843-848.
28. Maragakis N, Jackson M, Ganel R, Rothstein JD. Topiramate protects against motor neuron degeneration in organotypic spinal cord cultures but not in G93A SOD1 transgenic mice. Neurosci Lett. 2003;I338:107-110.
29. Cudkowicz ME, Shefher JM, Schoenfeld DA, et al. A randomized, placebo-controlled trial of topiramate in amyotrophic lateral sclerosis. Neurology. 2003;61:456-464.
30. Miller RG, Smith SA, Murphy JR, et al. A clinical trial of verapamil in amyotrophic lateral sclerosis. Muscle Nerve. 1996;19:511-515.
31. Ryberg H., Askmark H, Persson L. A double-blind randomized clinical trial in amyotrophic lateral sclerosis using lamotrigine: effects on CSF glutamate, aspartate, branched-chain amino acid levels and clinical parameters. Acta Neurol Scand. 2003;108:1-8.
32. Gredal O, Werdelin L, Bak S, et al. A clinical trial of dextromethorphan in amyotrophic lateral sclerosis. Acta Neurol Scand. 1997;96:8-13.
33. Bezzi P, Carmignoto G, Pasti L, et al. Prostaglandins stimulate calcium-dependent glutamate release in astrocytes. Nature. 1998;391:281-285.
34. Almer G, Romero N, Przedborski S. Upregulation of cyclooxygenase-2 in an animal model of familial amyotrophic lateral sclerosis. Neurology. 2000;54(Suppl 3):A304.
35. Yasojima K, Tourtellotte WW, McGeer EG, McGeer PL. Marked increase in cyclooxygenase-2 in ALS spinal cord. Neurology. 2001;57:952-956.
36. Pompl PN, Ho L, Bianchi M, McManus T, Qin W, Pasinetti GM. A therapeutic role for cyclooxygenase-2 inhibitors in a transgenic mouse model of amyotrophic lateral sclerosis. Faseb J. 2003; 17:725-727.
37. Azari MF, Profyris C, Le Grande MR, et al. Effects of intraperitoneal injection of rofecoxib in a mouse model of ALS. Eur J Neurol. 2005;12:357-364.
38. Mitsumoto H, Ikeda K, Holmlund T, et al. The effects of ciliary neurotrophic factor on motor dysfunction in wobbler mouse motor neuron disease. Ann Neurol. 1994;36:142-148.
39. Sendtner M, Schmalbruch H, Stockli KA, Carroll P, Kreutzberg GW, Thoenen H. Ciliary neurotrophic factor prevents degeneration of motor neurons in mouse mutant progressive motor neuronopathy. Nature. 1992;358:502-504.
40. Sendtner M, Holtmann B, Kolbeck R, Thoenen H, Barde YA. Brain-derived neurotrophic factor prevents the death of motoneurons in newborn rats after nerve section. Nature. 1992;360:757-759.
41. Kaspar BK, Llado J, Sherkat N, Rothstein JD, Gage FH. Retrograde viral delivery of IGF-1 prolongs survival in a mouse ALS model. Science. 2003;301:839-842.
42. A controlled trial of recombinant methionyl human BDNF in ALS: the BDNF Study Group (Phase III). Neurology. 1999;52:1427-1433.
43. Miller RG, Petajan JH, Bryan WW, et al. A placebo-controlled trial of recombinant human ciliary neurotrophic (rhCNTF) factor in amyotrophic lateral sclerosis. Ann Neurol. 1996;39:256-260.
44. Borasio GD, Robberecht W, Leigh PN, et al. A placebo-controlled trial of insulin-like growth factor-I in amyotrophic lateral sclerosis. European ALS/IGF-I Study Group. Neurology. 1998;51:583-586.
45. BDNF Study Group (Phase III). A controlled trial of recombinant methionyl human BDNF in ALS. Neurology. 1999;52:1427-1433.
46. Desnuelle C, Dib M, Garrel C, Favier A. A double-blind, placebo-controlled randomized clinical trial of alpha-tocopherol (vitamin E) in the treatment of amyotrophic lateral sclerosis. ALS Riluzole-Tocopherol Study Group. Amyotroph Lateral Scler Other Motor Neuron Disord. 2001;2:9-18.
47. Graf M, Ecker D, Horowski R, et al. High dose vitamin E therapy in amyotrophic lateral sclerosis as add-on therapy to riluzole: results of a placebo-controlled double-blind study. J Neural Transm. 2005;113:649-660.
48. Andreassen OA, Dedeoglu A, Klivenyi P, Beal MF, Bush AI. N-acetyl-L-cysteine improves survival and preserves motor performance in an animal model of familial amyotrophic lateral sclerosis. Neuroreport. 2000;11:2491-2493.
49. Louwerse ES, Weverling GW, Bossuyt PMM, Meyjes FEP, de Jong V. Randomized, double-blind, controlled trial of acetylcysteine in amyotrophic lateral sclerosis. Arch Neurol. 1995;52:559-564.
50. Klivenyi P, Ferrante RJ, Matthew RT, et al. Neuroprotective effects of creatine in a transgenic animal model of ALS. Nat Med. 1999;5:347-350.
51. Groenveld GJ, Veldink JH, van der Tweel I, et al. A randomized sequential trial of creatine in amyotrophic lateral sclerosis. Ann Neurol. 2003;53:437-445.
52. Shefner J, Cudkowicz ME, Schoenfeld D, et al. A clinical trial of creatine in amyotrophic lateral sclerosis. Neurology. 2004;63:1656-1661.
53. Carlile GW, Chalmers-Redman RM, Tatton NA, Pong A, Borden KE, Tatton WG. Reduced apoptosis after nerve growth factor and serum withdrawal: conversion of tetrameric glyceraldehyde-3-phosphate dehydrogenase to a dimer. Mol Pharmacol. 2000;57:2-12.
54. Murray L, ed. Physician's Desk Reference. Montvale, NJ: Thomson PDR; 2004.
55. Tikka T, Usenius T, Tenhunen M, Keinanen R, Koistinaho J. Tetracycline derivatives and ceftriaxone, a cephalosporin antibiotic, protect neurons against apoptosis induced by ionizing radiation. J Neurochem. 2001;78:1409-1414.
56. Yogev R, Shulman ST, Chadwick EG, Davis AT, Glogowski W. Once daily ceftriaxone for central nervous system infections and other serious pediatric infections. Pediatr Infect Dis. 1986;5:298-303.
57. Abe K, Manabe Y, Murakami T. [Gene therapy and neurotrophic factor treatment for amyotrophic lateral sclerosis]. Rinsho Shinkeigaku. 2001;41:1160-1161.
58. Jin KL, Mao XO, Greenberg DA. Vascular endothelial growth factor: direct neuroprotective effect in in vitro ischemia. Proc Natl Acad Sci USA. 2000;97:10242-10247.
59. Carmeliet P. Blood vessels and nerves: common signals, pathways and diseases. Nat Rev Genet. 2003;4:710-720.
60. Storkebaum E, Lambrechts D, Dewerchin M, et al. Treatment of motoneuron degeneration by intracerebroventricular delivery of VEGF in a rat model of ALS. Nat Neurosci. 2005;8:85-92.
61. Matthews R, Yang S, Browne S, Baik M, Beal MF. Coenzyme Q10 administration increases brain mitochondrial concentrations and exerts neuroprotective effects. Proc Natl Acad Sci USA. 1998;95:8892-8897.
62. Beal MF. Coenzyme Q10 as a possible treatment for neurodegenerative diseases. Free Radic Res. 2002;36:455-460.
63. Shults C, Oakes D, Kieburtz K, et al. Effects of coenzyme Q10 in early Parkinson's disease and evidence for slowing of 3 the functional decline. Arch Neurol 2002;59:1541-1550.
64. Ferrante KL, Shefner JM, Betensky RA, O'Brien ML, Taft JM, Yu H. Clinical trial of coenzyme Q10 in patients with amyotrophic lateral sclerosis. Amyotroph Lateral Scler Other Motor Neuron Disord. 2004;5(Suppl 2):24-26.
65. Yrjanheikki J, Tikka T, Keinanen R, Goldsteins G, Chan P, Koistinaho J. A tetracycline derivative, minocycline, reduces inflammation and protects against focal cerebral ischemia with a wide therapeutic window. Proc Natl Acad Sci USA. 1999;96:13496-13500.
66. Zhu S, Stavrovskiaya IG, Drozda M, et al. Minocycline inhibits cytochrome c release and delays progression of amyotrophic lateral sclerosis in mice. Nature. 2002;417:74-78.
67. Van Den Bosch L, Tilkin P, Lemmens G, Robberecht W. Minocycline delays disease onset and mortality in a transgenic model of ALS. Neuroreport. 2002;13:1067-1070.
68. Kriz J, Nguyen MD, Julien JP. Minocycline slows disease progression in a mouse model of amyotrophic lateral sclerosis. Neurobiol Dis. 2002;10:268-278.
69. Gordon PH, Moore DH, Gelinas DF, Qualls C, Meister ME, Werner J. Placebo-controlled phase I/II studies of minocycline in amyotrophic lateral sclerosis. Neurology. 2004;62:1845-1847.
70. Gonzalez de Aguilar J, Gordon J, Rene F, de Tapia M, Lutz-Bucher B, Gaiddon C. Alteration of the Bcl-x/Bax ratio in a transgenic mouse model of amyotrophic lateral sclerosis: evidence for the implication of the p53 signaling pathway. Neurobiol Dis. 2000;7:406-415.
71. Malaspina A, Kaushik N, de Belleroche J. Differential expression of 14 genes in amyotrophic lateral sclerosis spinal cord detected using gridded cDNA arrays. J Neurochem. 2001;77:132-145.
72. Yang Y, Hentati A, Deng HX, et al. The gene encoding alsin, a protein with three guanine-nucleotide exchange factor domains, is mutated in a form of recessive amyotrophic lateral sclerosis. Nat Genet. 2001;29:160-165.
73. Ishigaki S, Niwa J, Ando Y, et al. Differentially expressed genes in sporadic amyotrophic lateral sclerosis spinal cords-screening by molecular indexing and subsequent cDNA microarray analysis. FEBS Lett. 2002;531:354-348.
74. Hadano S, Hand CK, Osuga H, et al. A gene encoding a putative GTPase regulator is mutated in familial amyotrophic lateral sclerosis 2. Nat Genet. 2001;29:166-173.
75. Ryu H, Smith K, Camelo SI, et al. Sodium phenylbutyrate prolongs survival and regulates expression of anti-apoptotic genes in transgenic amyotrophic lateral sclerosis mice. J Neurochem. 2005;10:1471-4159.
76. Batulan Z, Shinder GA, Minotti S, et al. High threshold for induction of the stress response in motor neurons is associated with failure to activate HSF1. J Neurosci. 2003;23:5789-5798.
77. Kieran D, Kalmar B, Dick JR, Riddoch-Contreras J, Burnstock G, Greensmith L. Treatment with arimoclomol, a coinducer of heat shock proteins, delays disease progression in ALS mice. Nat Med. 2004;10:402-405.
78. Vincent AM, Backus C, Taubman AA, Feldman EL. Identification of candidate drugs for the treatment of ALS. Amyotroph Lateral Scler Other Motor Neuron Disord 2004;6:29-36.
79. Rothstein JD. Of mice and men: reconciling preclinical ALS mouse studies and human clinical trials. Ann Neurol. 2003;53:423-426.